VB4-A79
/ Vectus Biosystems
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 28, 2022
Vectus Biosystems progresses clinical trials of drug VB0004 for treating fibrosis and hypertension
(SmallCap Network)
- "Vectus Biosystems...has confirmed that it will move to the next phase of testing of its lead drug for treating fibrosis and hypertension....From a drug ‘library’ of 1,000 compounds, Vectus has also selected potential candidates for liver fibrosis (VB4-A32) and lung fibrosis (VB4-A79)"
New trial • Idiopathic Pulmonary Fibrosis
1 to 1
Of
1
Go to page
1